Antibody-drug conjugate (ADC) development in non–small cell lung cancer (NSCLC) has converged on a handful of targets and one dominant payload class, and the next gains may depend more on payload, linker, and patient selection than on the target itself, according to Alissa Cooper, MD, of Dana-Farber Cancer Institute in Boston, Massachusetts.1 Speaking during a presentation at the 44th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow, Cooper reviewed established targets, emerging targets, and new payload designs, the last of which she called "our area of greatest need."1
Key Takeaways on Novel ADC Constructs and Targets in NSCLC
- Target expression measured by conventional immunohistochemistry has not reliably predicted benefit from antibody-drug conjugates in NSCLC, and better biomarkers are needed to identify which patients will respond.
- The efficacy and tolerability of an antibody-drug conjugate depend on its payload, linker, and therapeutic window, not only on the antigen it targets.
- Because most current agents share a topoisomerase I inhibitor payload, novel payload mechanisms and dosing strategies beyond the maximum tolerated dose will be key to effective sequencing.
Can TROP2 expression predict who benefits?
About half of recent ADC trials have required biomarker selection by immunohistochemistry (IHC) or genomic testing, which Cooper said oversimplifies patient selection. "While we have biomarker-selected patient selection trials, I do think that we need to figure out more deeply what are the patients that are going to benefit," she said.1
One attempt to look deeper is the TROP2 normalized membrane ratio (NMR), a computational pathology score assessed by quantitative continuous scoring (QCS).2 In the biomarker-evaluable population of the phase 3 TROPION-Lung01 trial (NCT04656652), patients with QCS-NMR–positive tumors who received datopotamab deruxtecan (Dato-DXd; Datroway) had an objective response rate (ORR) of 32.7% vs 10.3% with docetaxel and a median progression-free survival (PFS) of 6.9 vs 4.1 months (HR, 0.57; 95% CI, 0.41-0.79). In NMR-negative patients, the curves overlapped (HR, 1.16; 95% CI, 0.79-1.70).2
That signal did not hold in EGFR-mutated disease. Among 68 patients with EGFR-mutated nonsquamous NSCLC from TROPION-Lung01 and the phase 2 TROPION-Lung05 trial (NCT04484142), median PFS with Dato-DXd was 5.8 months in NMR-positive and 5.7 months in NMR-negative patients (HR, 0.95; 95% CI, 0.53-1.72).3 "[This] calls into question, what is the biomarker for these patients?" Cooper said. "Is it the EGFR mutation itself?"1
How are next-generation TROP2-directed ADCs performing?
Sacituzumab tirumotecan (sac-TMT) now has randomized data against a demanding comparator. In the phase 3 OptiTROP-Lung04 trial (NCT05870319), which enrolled patients with EGFR-mutated NSCLC after EGFR TKI progression, sac-TMT improved PFS vs platinum doublet chemotherapy,4 and the final analysis showed a median overall survival (OS) of 25.9 months vs 17.4 months (HR, 0.69; 95% CI, 0.54-0.89).5 No patient discontinued sac-TMT because of treatment-related adverse events, and interstitial lung disease (ILD)/pneumonitis occurred in 1 patient.5 "I don't think we've seen this randomized control in this space before, especially with such a strong control arm as platinum doublet," Cooper said.1
She found the frontline data even more striking. In the phase 3 OptiTROP-Lung06 trial (NCT06711900), sac-TMT plus pembrolizumab (Keytruda) produced a median PFS by blinded independent central review of 15.0 months vs 5.7 months with chemotherapy plus pembrolizumab in patients with PD-L1–negative nonsquamous NSCLC (HR, 0.49; 95% CI, 0.36-0.65; P < .0001). Grade 3 or higher adverse events were less frequent with sac-TMT (47.6% vs 60.6%).6,13 "This was very, very encouraging data, in my opinion," she said.1
What do next-generation HER2- and MET-directed ADCs add?
Trastuzumab rezetecan (SHR-A1811), which pairs a second-generation topoisomerase I inhibitor payload with a stability-engineered linker, produced an ORR of 73% with an ILD rate of 5% in patients with previously treated HER2-mutant NSCLC in the phase 2 portion of the phase 1/2 HORIZON-Lung trial (NCT04818333) in China.7
For MET, telisotuzumab adizutecan (Temab-A) yielded an ORR of 69% and a median PFS of 11.0 months among patients with MET-amplified NSCLC (n = 29) in the first-in-human phase 1 M21-404 trial (NCT05029882), with an adjudicated ILD rate of 4% and no treatment-related deaths.8 "This is the trend we're starting to see a little bit more of: this wider therapeutic window in these next-generation agents, a little bit more efficacy and a little bit less toxicity," Cooper said.1